Chronic Myeloid Leukemia Patients Sensitive and Resistant to Imatinib Treatment Show Different Metabolic Responses

The BCR-ABL tyrosine kinase inhibitor imatinib is highly effective for chronic myeloid leukemia (CML). However, some patients gradually develop resistance to imatinib, resulting in therapeutic failure. Metabonomic and genomic profiling of patients' responses to drug interventions can provide no...

Descripción completa

Detalles Bibliográficos
Autores principales: A, Jiye, Qian, Sixuan, Wang, Guangji, Yan, Bei, Zhang, Sujiang, Huang, Qing, Ni, Lingna, Zha, Weibin, Liu, Linsheng, Cao, Bei, Hong, Ming, Wu, Hanxin, Lu, Hua, Shi, Jian, Li, Mengjie, Li, Jianyong
Formato: Texto
Lenguaje:English
Publicado: Public Library of Science 2010
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2951899/
https://www.ncbi.nlm.nih.gov/pubmed/20949032
http://dx.doi.org/10.1371/journal.pone.0013186

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2951899/
https://www.ncbi.nlm.nih.gov/pubmed/20949032
http://dx.doi.org/10.1371/journal.pone.0013186

Ejemplares similares